Improving immune responses after blood cell transplants
Immune Modulation After Allogeneic HCT
This study is looking at ways to help your immune system better fight cancer after you’ve had a blood cell transplant, by figuring out why some people have setbacks like disease relapse or complications, and it will test new treatments to improve your recovery while keeping you safe.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10695921 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune system's ability to fight cancer after patients receive blood cell transplants. It aims to understand why some patients experience disease relapse or complications like graft versus-host disease (GVHD) after the transplant. By studying both donor and patient immune factors, the research seeks to develop new strategies to boost the immune response against remaining cancer cells while minimizing harmful reactions against the patient's own tissues. The approach includes clinical trials testing innovative therapies to improve outcomes for patients undergoing this treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hematologic malignancies who are undergoing or have undergone allogeneic hematopoietic cell transplantation.
Not a fit: Patients who have not received a blood cell transplant or those with solid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better survival rates and quality of life for patients undergoing blood cell transplants.
How similar studies have performed: Previous research has shown promise in enhancing immune responses in transplant patients, indicating that this approach could lead to significant advancements.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Soiffer, Robert Jon — Dana-Farber Cancer Inst
- Study coordinator: Soiffer, Robert Jon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.